PETRI DISH PERSPECTIVES

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore the story of Enveda Biosciences , one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast synthetic chemical libraries, Enveda is using artificial intelligence, metabolomics, and mass spectrometry to unlock the world's largest and largely un...

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore the story of Isomorphic Labs , Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mysteries, protein folding, to building an AI-native pharmaceutical company, Isomorphic Labs is attempting to fundamentally change how medici...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology p...

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Business System (DBS), the acquisition strategy that reshaped biotechnology, the landmark purchases of Beckman Coulter, Pall, and Cytiva, and why Dana...

Send us Fan Mail In this episode of Petri Dish Perspectives , we dive into the rise of Hims & Hers Health , the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscrip...

Send us Fan Mail In this episode of Petri Dish Perspectives , we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for g...

Send us Fan Mail In this episode of Petri Dish Perspectives , we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "a...

Send us Fan Mail This week on Petri Dish Perspectives , we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe buil...

Send us Fan Mail This week on Petri Dish Perspectives , we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufactur...

Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives , we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the lead...

Send us Fan Mail In this episode of Petri Dish Perspectives , we break down the 340B Drug Pricing Program , a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine. 🎧 Listen now, stay curi...

Send us Fan Mail What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy . From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from tre...

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed , we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology. This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from...

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed , we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs). From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoG...

Send us Fan Mail In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that al...

Send us Fan Mail In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology. We break down...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Suppo...

Send us Fan Mail In this episode of Petri Dish Perspectives , we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.” We break down Ginkgo’s unique business model, partneri...

Send us Fan Mail From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech. In this episode of Petri Dish Perspectives: Biotech Unleashed , we break down how Dilip Shanghvi transformed a niche generics business into one of the largest pharmaceutical companies in the world. We expl...

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic...

Send us Fan Mail Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed , we break down how BioMarin became one of the most influential rare-disease biotech companies in the...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #Pharm...

Send us Fan Mail Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything. In this episode of Petri Dish Perspectives: Biotech Unleashed , we explore how BioNTech evolved from an academic vision into one of the most important biotechnology c...